Alteration of the immunological synapse in lung cancer: A microenvironmental approach

Clinical and Experimental Immunology

Volumn 154, Issue 1, 2008, Pages 48-55

  Derniame, S ^a,b   Vignaud, J M ^b   Faure, G C ^b   Bene M C ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Immune escape to cancer; Immunohistology; Lung cancer; Pneumocytes; T cells

Indexed keywords

CD3 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADULT; ARTICLE; CANCER IMMUNOLOGY; CANCER PATIENT; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODETECTION; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

ADENOCARCINOMA; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS;

EID: 51349090152     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03727.x     Document Type: Article

References (32)

1. Garcia-lora A, Algarra I, Collado A, Garrido F. Tumor immunology, vaccination and escape strategies. Eur J Immunogenet 2003 30 : 177 83.
2. Gabrilovich D, Pisarev V. Tumor escape from immune response: mechanisms and targets of activity. Curr Drug Targets 2003 4 : 525 36.
3. Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004 53 : 79 85.
4. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-β inhibitors. Invest New Drug 2003 21 : 21 32.
5. Ben-Hur H, Cohen O, Schneider D et al. The role of lymphocytes and macrophages in human breast tumorigenesis: an immunohistochemical and morphometric study. Anticancer Res 2002 22 : 1231 8.
6. Zhang L, Yang N, Conejo-Garcia JR et al. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 2003 9 : 264 72.
7. Ohno S, Tachibana M, Fujii T, Ueda S, Kubota H, Nagasue N. Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. Int J Cancer 2002 97 : 770 4.
8. Salgaller ML. The development of immunotherapies for non-small cell lung cancer. Expert Opin Biol Ther 2002 2 : 265 78.
9. Benlalam H, Labarriere N, Linard B et al. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur J Immunol 2001 31 : 2007 15.
10. Saeterdal I, Bjorheim J, Lislerud K et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 2001 98 : 13255 60.
11. Mami-Chouaib F, Echchakir H, Dorothee G, Vergnon I, Chouaib S. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev 2002 188 : 114 21.
12. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002 12 : 3 13.
13. Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004 53 : 865 78.
14. Delon J, Germain RN. Information transfer at the immunological synapse. Curr Biol 2000 10 : R923 33.
15. Tartour E, Latour S, Mathiot C et al. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995 63 : 205 12.
16. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313 : 1960 4.
17. Fierabracci P, Pinchera A, Campani D, Pollina LE, Giustarini E, Giani C. Association between breast cancer and autoimmune thyroid disorders: no increase of lymphocytic infiltrates in breast malignant tissues. J Endocrinol Invest 2006 29 : 248 51.
18. Castelli C, Maeurer MJ. The T-cell response in patients with cancer. Adv Cancer Res 2002 86 : 149 93.
19. Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA. MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. Immunobiology 2006 211 : 619 25.
20. McDermott R, Beuvon F, Pauly M et al. Tumor antigens and antigen-presenting capacity in breast cancer. Pathobiology 2002 70 : 324 32.
21. Morimoto Y, Toyota M, Satoh A et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br J Cancer 2004 90 : 844 52.
22. Shibuya TY, Nugyen N, Mclaren CE et al. Clinical significance of poor CD3 response in head and neck cancer. Clin Cancer Res 2002 8 : 745 51.
23. Nakagomi M, Petersson M, Magnusson I et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993 53 : 5610 12.
24. Ishigami S, Natsugoe S, Miyazono F et al. CD3 zeta expression of regional lymph node and peripheral blood lymphocytes in gastric cancer. Anticancer Res 2004 24 : 2123 6.
25. Esendagli G, Bruderek K, Goldmann T et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008 59 : 32 40.
26. Glanville AR, Tazelaar HD, Theodore J et al. The distribution of MHC class I and II antigens on bronchial epithelium. Am Rev Respir Dis 1989 139 : 330 4.
27. Broderick L, Brooks SP, Takita H, Baer AN, Bernstein JM, Bankert RB. IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells. Clin Immunol 2006 118 : 159 69.
28. Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 2004 11 : 665 80.
29. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 2006 55 : 1159 84.
30. Seddiki N, Santner-Nanan B, Tangye SG et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006 107 : 2830 8.
31. Shimizudani N, Murata H, Kojo S et al. Analysis of T cell receptor V(beta) gene expression and clonality in bronchoalveolar fluid lymphocytes from a patient with chronic eosinophilic pneumonitis. Lung 2001 179 : 31 41.
32. Stevenson CS, Coote K, Webster R et al. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol 2005 288 : L514 22.